Page 79 - MI-2-3

Microbes & Immunity Natural phage patentability in the U.S.

Table A1. (Continued)
Patent Application form (20210228659-A1) Granted form (11779617-B2) Note
11. The composition of claim 1, wherein 10. The composition of claim 1, wherein the composition Unchanged
the composition is administered to a is administered to a mammal in a dosage range
mammal in a dosage range between between about 1×10 to about 1×10 PFU of each
11
7
about 1×10 to about 1×10 PFU of each phage at least once daily.
7
11
phage at least once daily.
12. A bacteriophage composition 11. A bacteriophage composition comprising two or more Unchanged
comprising two or more purified purified bacteriophage populations selected from Sa87,
bacteriophage populations selected from J-Sa36, and Sa83.
Sa87, J-Sa36, and Sa83.
13. The bacteriophage composition of claim 12. The bacteriophage composition of claim 11, further Unchanged
12, further comprising an antibiotic. comprising an antibiotic.
14. The bacteriophage composition of claim 13. The bacteriophage composition of claim 11, further Unchanged
12, further comprising a pharmaceutically comprising a pharmaceutically acceptable carrier,
acceptable carrier, diluent, excipient, or diluent, excipient, or combination thereof.
combination thereof.
15. The bacteriophage composition of claim 14. The bacteriophage composition of claim 11, wherein Unchanged
12, wherein the composition comprises the composition comprises 1×10 PFU/mL per phage.
11
1×10 PFU/mL per phage.
11
16. The bacteriophage composition of claim 15. The bacteriophage composition of claim 14, wherein Unchanged
15, wherein the composition has a final the composition has a final endotoxin level
endotoxin level <1000 EU/mL. <1000 EU/mL.
17. The composition of claim 16, wherein 16. The composition of claim 15, wherein the composition Unchanged
the composition is diluted 1:10. is diluted 1:10.
18. The composition of claim 16, wherein 17. The composition of claim 15, wherein the composition Unchanged
the composition is diluted 1:100. is diluted 1:100.
19. The composition of claim 16, wherein 18. The composition of claim 15, wherein the composition Unchanged
the composition is administered to a is administered to a mammal in a dosage range
mammal in a dosage range between between about 1×10 to about 1×1011 PFU of each
7
7
11
about 1×10 to about 1×10 PFU of each phage at least once daily.
phage at least once daily.
20. A kit comprising: 19. A kit comprising: Unchanged
a. bacteriophage composition according a. bacteriophage composition according to claim 1;
to claim 1; and and
b. instructions for use of the same. b. instructions for use of the same.
21. The kit of claim 20, further comprising 20. The kit of claim 19, further comprising an antibiotic Unchanged
an antibiotic and instructions for the and instructions for the use of the same in
use of the same in combination with the combination with the bacteriophage composition.
bacteriophage composition.
22. The kit of claim 21, wherein said 21. The kit of claim 20, wherein said instructions are for Unchanged
instructions are for use of the same in use of the same in treating a S. aureus infection.
treating a S. aureus infection, preferably
a S. aureus pulmonary infection.
22. The kit of claim 21, wherein the S. aureus infection is a Unchanged
pulmonary infection.
Abbreviations: PFU: Plaque-forming unit; LMG: Laboratory of Microbiology, Ghent University; P. aeruginosa: Pseudomonas aeruginosa; S. aureus:
Staphylococcus aureus.

Volume 2 Issue 3 (2025) 71 doi: 10.36922/mi.4758